Welcome to our dedicated page for Evolent Health news (Ticker: EVH), a resource for investors and traders seeking the latest updates and insights on Evolent Health stock.
Evolent Health, Inc. (NYSE: EVH) plays a pivotal role in the healthcare sector by supporting health systems and physician organizations in their transition to value-based care and population health management. Headquartered in Arlington, Virginia, Evolent is backed by major entities such as The Advisory Board Company, University of Pittsburgh Medical Center Health Plan, and TPG Growth. The company’s core business revolves around providing integrated specialty care management services, total cost of care management, and health plan administration through an all-inclusive platform.
Evolent specializes in managing complex conditions in fields such as oncology, cardiology, and musculoskeletal markets, aiming to simplify healthcare and make it more affordable. The company's recent achievements include exceeding profitability expectations in the third quarter of 2023, adding new operating partnerships, and enhancing its financial outlook for the year. Evolent reported robust financial health with $184.5 million in cash and cash equivalents as of September 30, 2023.
The company’s culture is centered around collaboration, innovation, and a supportive work environment. Benefits like treadmill desks, healthy snacks, and wellness challenges underscore its commitment to employee well-being.
Notably, Evolent is also venturing into AI-driven healthcare solutions, as evidenced by its recent agreement to acquire Machinify Auth, a software platform that enhances clinical quality through advanced AI. This acquisition is expected to significantly improve the speed and efficiency of clinical reviews for various conditions.
In summary, Evolent Health continues to be a significant player in the healthcare industry, driving better health outcomes and financial performance through innovative solutions.
Evolent Health has nominated Richard Jelinek for election to its Board of Directors at the upcoming annual meeting scheduled for June 8, 2023. Jelinek, who is a managing partner at Czech One Capital Partners, has extensive experience in the health care sector, including executive roles at Aetna and CVS Health. His appointment coincides with the departure of current board member David Farner and former Chairman Frank Williams, both set to leave the board in June 2023. Evolent's leadership believes Jelinek's expertise will enhance the board's perspectives and support the company’s mission in value-based specialty care. The board expressed gratitude for the contributions of Farner and Williams, emphasizing the importance of evolving governance.
Evolent Health (NYSE: EVH) announced on March 29, 2023, an agreement with Centene Corporation (NYSE: CNC) to enhance its Technology and Services solution for oncology care. This partnership will extend Evolent's oncology services to Centene’s Medicare Advantage members across the nation, deepening their existing collaboration in the specialty care market. Both companies aim to optimize oncology outcomes while managing costs effectively. Evolent's established platform, backed by scientific advisory boards, focuses on clinical quality and financial accountability, ensuring improved care delivery for patients.
Evolent Health (NYSE: EVH) announced participation in several upcoming investor conferences. Chief Financial Officer John Johnson and Vice President of Investor Relations Seth Frank will represent the company. Details include:
- March 7, 2023: Cowen 43rd Annual Healthcare Conference in Boston at 10:30 a.m. ET.
- March 13, 2023: Annual Jefferies Value-Based Healthcare Summit in Miami Beach (no webcast).
- March 14, 2023: Barclays Global Healthcare Conference in Miami Beach at 3:35 p.m. ET.
Webcast recordings will be available on the investor relations section of Evolent's website. Evolent Health focuses on clinical and administrative solutions that improve health care affordability and accessibility.
Evolent Health (NYSE: EVH) reported Q4 and full-year 2022 financial results, showing significant growth. Q4 revenue reached $382.4 million, up 54.0% year-over-year, while full-year revenue totaled $1.35 billion, a 48.9% increase. Despite revenue growth, the company faced a net loss of $11.3 million for Q4, resulting in a net loss margin of (3.0)%. Total Lives on Platform expanded to 20.6 million. For 2023, Evolent secured new partnerships, including a significant sale expected to generate over $250 million in revenue for 2024. The company anticipates first-quarter revenue between $420 million and $440 million and full-year revenue of approximately $1.92 to $1.96 billion.
Evolent Health, Inc. (NYSE: EVH) has announced that it will release its fourth quarter 2022 financial results on February 22, 2023, after market close. A conference call will follow at 5:00 p.m. Eastern Time. Shareholders and interested parties can listen to the call by dialing 855.940.9467 for domestic calls or 412.317.6034 for international access, referencing the Evolent Health call.
An audio playback will be available on the company's investor relations website for 90 days post-call. Evolent Health is known for delivering clinical and administrative solutions that enhance health care affordability and efficiency.
FAQ
What is the current stock price of Evolent Health (EVH)?
What is the market cap of Evolent Health (EVH)?
What is the primary business of Evolent Health, Inc.?
Where is Evolent Health headquartered?
What recent financial achievements has Evolent Health reported?
What are some of the core services provided by Evolent Health?
What recent acquisition did Evolent Health announce?
Who are some of the backers of Evolent Health?
What are the primary specialty care areas Evolent focuses on?
How does Evolent Health view its company culture?
What is the significance of Evolent’s acquisition of Machinify Auth?
How has Evolent Health performed financially in recent quarters?
